lundi 29 septembre 2014

Promising results shown with targeted approaches in subsets of non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data.

Promising results shown with targeted approaches in subsets of non-small cell lung cancer

Aucun commentaire:

Enregistrer un commentaire